Episode Description
Over the past week, everyone has had launches on the brain – thanks largely to the Artemis II rocket and its ongoing lunar flyby mission.
However, there are a couple of health-related launches that are the focus of this week’s episode.
First up is the launch of HayloARC, a health-focused demand-side platform – better known as a DSP.
HayloARC is available for use by advertisers and medical marketing agencies seeking to better interface with HCPs and patients.
To accomplish this, HayloARC utilizes first-party HCP data derived from 30-plus medical publications owned by Haymarket Media, the parent company of MM+M.
For the feature conversation, editor-at-large Steve Madden sits down with Louis Naimoli, VP of programmatic business development and strategy at Haymarket, about what HayloARC is, how it’s differentiated from other DSPs and what it offers programmatic buyers in medical marketing.
Then, during our Trends segment, we’re talking about how the fight for GLP-1 supremacy between Novo Nordisk and Eli Lilly has shifted to the oral obesity pill battlefield.
We discuss Novo rolling out a multimonth subscription program for Wegovy and the FDA’s approval of Lilly’s daily oral weight loss drug Foundayo.
Music: “Deep Reflection” by DP and Triple Scoop Music.
Check us out at: mmm-online.com
Follow us:
YouTube: @MMM-online
TikTok: @MMMnews
Instagram: @MMMnewsonline
Twitter/X: @MMMnews
LinkedIn: MM+M
To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.
Music: “Deep Reflection” by DP and Triple Scoop Music.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Listen On
